A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Inclusion Criteria:
Note: Maintenance therapy OR hormonal therapies should not be counted as a separate therapy.
Note: Patients who have not received prior bevacizumab must be deemed medically inappropriate OR ineligible to receive bevacizumab, refused to receive bevacizumab, or been unable to receive bevacizumab due to lack of access.
Exclusion Criteria:
Los Angeles, California 90048, United States
San Francisco, California 94158, United States
Greeley, Colorado 80631, United States
Savannah, Georgia 31405, United States
Scarborough, Maine 04074, United States
South Weymouth, Massachusetts 02190, United States
Saint Louis Park, Minnesota 55416, United States
St Louis, Missouri 63110, United States
Port Jefferson Station, New York 11776, United States
Columbus, Ohio 43210, United States
Willow Grove, Pennsylvania 19090, United States
Zhejiang, Hangzhou Province 310009, China
Wuhan, Hubei 430022, China
Zhejiang, Shangcheng District, Hangzhou Province 310003, China
Xi’an, Shanxi 710061, China
Taiyuan, Xinghualing District, Shanxi Province 030001, China